Immunome Prices Public Offering Of 10M Common Stock At $20/Share
Portfolio Pulse from Benzinga Newsdesk
Immunome has announced a public offering of 10 million shares at $20 each, expecting to raise $200 million before expenses. The underwriters have an option to buy an additional 1.5 million shares. The offering is set to close on February 16, 2024, pending customary closing conditions.
February 14, 2024 | 7:38 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Immunome aims to raise $200M through a public offering of 10M shares at $20 each, with a potential additional sale of 1.5M shares to underwriters.
The announcement of a public offering can have mixed impacts on a company's stock price. On one hand, it can dilute existing shares, potentially lowering the stock price. On the other hand, the influx of capital can be viewed positively if the funds are used for growth or to strengthen the balance sheet. Given the size of the offering and the current information, it's challenging to predict the exact short-term price direction, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100